No Data
No Data
東瑞製葯:2023 年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Dongrui Pharmaceuticals (02348.HK) was granted an additional 60,000 shares of common stock by Li Qiling, worth approximately HK$70,200
On April 5, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 5, Li Qiling increased her common share holdings of $Dongrui Pharmaceuticals (02348.HK) by $60,000 at an average price of HK$1.17 per share on April 2, worth about HK$70,200. After increasing her holdings, Li Qiling's latest shareholding was 704 million shares, with a good position ratio of 46.94%. This transaction involves another related party: Xiong Rongli. Image source: Stock Exchange Equity Disclosure (partial table of this incident) What is equity disclosure? According to the requirements of the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their shares in listed companies
No Data